Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

Overview of attention for article published in BMC Medicine, March 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 12,267 followers.

It's hard to think beyond targeting AR in metastatic prostate cancer when it keeps being an effective target. A new AR antagonist, SHR3680. Paper: https://t.co/2HdX2JwPHv #ASCO22 https://t.co/zEE3y0akqK

05 Jun 2022

Reply Repost Favourite

A phase I/II trial studying activity and safety of #SHR3680, a novel #antiandrogen, in patients with metastatic castration-resistant #prostatecancer. Read it here: https://t.co/Xz5PA2OXF6 https://t.co/69x4utSfaw

09 Mar 2022

Reply Repost Favourite

NEW in BMC Medicine: Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial https://t.co/Xz5PA2OXF6

07 Mar 2022

Reply Repost Favourite

New article: Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial https://t.co/H3X6aDJQTt #prostatecancer #oncology https://t.co/N6VKnmNR3y

04 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.